Wang M
Br J Cancer. 1971 Jun;25(2):315-22. doi: 10.1038/bjc.1971.41.
Hyperimmune heterologous serum produced in sheep against mouse Ehrlich ascites tumour cells was absorbed with normal mouse tissue and fractionated by DEAE column chromatography into IgG1 and IgG2 fractions. In vitro cytotoxicity test showed that sheep anti-Ehrlich ascites tumour IgGl fraction was cytotoxic to (51)Cr labelled tumour cells whereas IgG2 had no cytotoxic effect. Pretreatment of the tumour cells with the non-cytotoxic IgG2 fraction slightly inhibited the cytotoxic action of IgG1 in vitro.When EAT cells were coated with either IgG1 or IgG2 by preincubation in vitro before injecting intraperitoneally into mice, both fractions protected the animals against tumour growth. Injection of IgG2 and IgGl fractions separately, one before and the other after the injection of EAT cells, resulted in partial protection only. The difference encountered between the in vitro and in vivo findings could be attributed to the host defence mechanisms involved in the in vivo test system.
用绵羊制备的针对小鼠艾氏腹水瘤细胞的超免疫异种血清,经正常小鼠组织吸收后,通过DEAE柱层析分离为IgG1和IgG2组分。体外细胞毒性试验表明,绵羊抗艾氏腹水瘤IgG1组分对(51)Cr标记的肿瘤细胞具有细胞毒性,而IgG2则无细胞毒性作用。用无细胞毒性的IgG2组分预处理肿瘤细胞,在体外可轻微抑制IgG1的细胞毒性作用。当通过体外预孵育使艾氏腹水瘤细胞包被IgG1或IgG2后再腹腔注射到小鼠体内时,两种组分均能保护动物免受肿瘤生长。分别注射IgG2和IgG1组分,一种在注射艾氏腹水瘤细胞之前,另一种在之后,仅产生部分保护作用。体外和体内研究结果之间的差异可能归因于体内试验系统中涉及的宿主防御机制。